1. Home
  2. Products
  3. Customized ADCs
  4. CD28
  5. Anti-CD28 (lumretuzumab)-MC-MMAF ADC

Anti-CD28 (lumretuzumab)-MC-MMAF ADC (CAT#: ADC-W-2278)

This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • CD28
  • Alternative Names
  • CD28; CD28 molecule; CD28 antigen (Tp44); T-cell-specific surface glycoprotein CD28; T cell specific surface glycoprotein; CD28 antigen; Tp44; MGC138290;
  • Target Entrez Gene ID
  • 940
  • Overview
  • The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.
  • Overview
  • Humanized Anti-CD28 IgG1-kappa antibody, lumretuzumab
  • Generic name
  • lumretuzumab
  • Host animal
  • Mouse
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-2278. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2333 Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-2330 Anti-CD28 (lulizumab pegol)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2280 Anti-CD28 (lumretuzumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2332 Anti-CD28 (lulizumab pegol)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2276 Anti-CD28 (lumretuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-114 Anti-CD33-Mc-MMAF ADC-3 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-2612 Anti-MS4A1 (Rituximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-485 Anti-EphA2-Mc-MMAF ADC-1 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-478 Anti-ENPP3-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
CAT# Product Name Linker Payload
ADC-W-2579 Anti-CEACAM5-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2612 Anti-MS4A1 (Rituximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2585 Anti-EGFR (Zalutumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2567 Anti-MUC16 (Sofituzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-AA-063 Anti-HIgG(Fab)-N-MMAF ADC Noncleavable linkers MMAF

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.